Bilateral and multifocal central serous chorioretinopathy after injecting triamcinolone into a chalazion

Asensio-Sánchez, V.M.; Pareja-Aricò, Luis; Valentín-Bravo, J.

doi:10.1016/j.oftale.2019.12.003

Cited by 2 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several complications with TA injections were reported including central serous chorioretinopathy,[ 10 11 ] 1 eyelid fat atrophy and depigmentation,[ 12 13 ] anterior segment ischemia[ 14 ] and accidental globe penetration. [ 15 ] Care should be taken while injecting TA.…”

Section: Discussionmentioning

confidence: 99%

Extralesional triamcinolone acetonide injection in the treatment of small chalazion

Jiao

Ren

Gan

et al. 2023

Indian Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose: To evaluate the effect of extralesional triamcinolone acetonide (TA) injection in the treatment of small chalazion (diameter ≤ 5 mm). Methods: Prospective interventional clinal study that included patients diagnosed as chalazion of small size not responding to conservative management for at least 2 weeks. All patients were treated with extralesional TA injection (4 mg). Successful resolution of a chalazion was defined as a decrease in size to 1 mm or smaller. Results: Thirty-eight patients were included in the study. The resolution was achieved in 33 (87%) patients. Nineteen (50%) patients had complete resolution after the first injection, and 13 (34.2%) patients had complete resolution after the second injection. Chalazion near the lower punctum needed more times of injections than those elsewhere (P = 0.02). Conclusions: Extralesional TA injection is effective in the treatment of both primary and recurred small chalazia. It is a simple and cost-saving procedure and can be considered an alternative first-line treatment for small chalazion.

show abstract

Section: Discussionmentioning

confidence: 99%

Extralesional triamcinolone acetonide injection in the treatment of small chalazion

Jiao

Ren

Gan

et al. 2023

Indian Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…In most studies, taking corticosteroid therapy is known as a major risk factor whatever its dosage form, sometimes even at low doses, Asensio-Sánchez VM published in January 2020 a case of bilateral central serous chorioretinopathy, 1 month after a Intra-tarsal injection of Triamcinolone for a chalazion, the CRSC spontaneously resolved well 3 months after diagnosis [7] Nowadays, the definition of persistent CSCR is debatable, but it is most often defined as a DSR lasting more than 3 months or recurrence of the disease within one year [8] The period of persistence is variable according to the authors (between 3 and 6 months), but the most cited periods are 3 and 4 months.…”

Section: Discussionmentioning

confidence: 99%

Eplerenone in the Central Serous Chorioretinopathy Chronic

Khamaily¹,

Salem²,

Tarib³

et al. 2020

IJOVS

View full text Add to dashboard Cite

Central serous chorioretinitis is a relatively common eye condition. It is a maculopathy of the young subject, characterized by the presence of a retinal serous detachment, usually located at the posterior pole, associated with changes in the pigment epithelium. Materials and methods: a prospective study was conducted between Mars 2018 and Mars 2020 at the Mohammed V military hospital in Rabat, in 11 patients treated with eplerenone for a chronic CRSC evolving for at least 3 months with repercussions on visual acuity, at the dose of 25 mg per day the first week, then 50 mg per day for an average treatment duration of 15 weeks. For each patient, visual acuity and macular OCT (central thickness of the retina) were evaluated before treatment and at 1, 3 and 6 months. Results: The mean age of the patients was 32,54 ± 6,78. 11 men. All patients were under stress, and just two patient reported the notion of taking corticosteroids. The average duration of progression of the pathology before treatment was 20 weeks. A clear improvement in visual acuity (logMAR) was observed in 9 patients: mean visual acuity increased from 0,7 at admission to 0,69 at 1 month (p: 0.014), 0,4 at 3 months (p: 0.013) and 0,28 at 6 months (p: 0.025). The mean central macular thickness decreased from 423 ± 91 µm before treatment, 317 ± 82 µm at 1 month and 292 ± 73,6 µm at 3 months and 251± 94 µm at 6 months (p 0.026, 0.01 and 0.038 respectively). 5 patients had a complete disappearance of SRF at 3 months. 1 other patients had a complete disappearance of the DSR at 6 months. The treatment was stopped for 3 patients, including 1 at 4 weeks for severe muscle cramps, and hyperkaliema for the 2 others at 10 weeks ans 11 weeks of treatment. Conclusion: In our study, the introduction of eplerenone resulted in significant improvement in both anatomical and functional outcomes in patients with chronic CSCR.

show abstract

Bilateral and multifocal central serous chorioretinopathy after injecting triamcinolone into a chalazion

Cited by 2 publications

References 10 publications

Extralesional triamcinolone acetonide injection in the treatment of small chalazion

Extralesional triamcinolone acetonide injection in the treatment of small chalazion

Eplerenone in the Central Serous Chorioretinopathy Chronic

Contact Info

Product

Resources

About